title: [Influence of rosuvastatin in endothelial function and oxidative stress, in patients with acute coronary syndrome].
abstract: OBJECTIVE
  The endothelial function is the cornerstone of several cardiovascular disease. In this trial we compared how the Nitric Oxide (NO) and Oxidative Stress (OS) serum levels, as surrogate markers of endothelial function, change in patients who received (or not) rosuvastatin during the first seven days of an acute coronary syndrome (ACS).
  
  
  METHODS
  Twenty-two patients with ACS (age:66 +/- 9 years, gender: ten female and 12 male) were randomized in two groups. Patients in the first group (G1) received the conventional treatment for an ACS, plus placebo. The other group (G2) additionally received a daily oral dose of 40 mg of rosuvastatin. We measured the blood levels of nitrates and OS in both groups twice: at baseline (admission to Intensive care unit) and seven days after. The statistical analysis was performed using the paired t-test or the Chi2 test depending of the variables. Statistical significance was considered with a p < 0.05.
  
  
  RESULTS
  Groups (G1 and G2) differed statistically on age (G1=71 years +/- 10 vs. G2 63 +/- 9 years, p=0.04). After 7 days of the ACS onset, ON levels diminished on 21% (p=0.17) in G1, but raised on 24% in the group who re- ceived rosuvastatin (p=0.005), with statistically difference between groups (p=0.005). On the other hand, the OS, augmented statistically on both groups: G1 (17%, p<0.001) and G2 (13%, p<0.001), without any difference between groups (p=0.77).
  
  
  CONCLUSIONS
  The endothelial dysfunction in the first days of an ACS is accentuated, but with the use of rosuvastatina, the endothelial function improves. In contrast, the OS increase in both groups, without differences between groups.
authors.affiliation: Departamento Cardiovascular del Instituto de la Ciencia y Medicina Genómica, Torreón Coahuila. sandra_nagay@yahoo.com.mx
authors.forename: Sandra
authors.initials: S
authors.lastname: Nagay Hernández
authors.forename: Juan José
authors.initials: JJ
authors.lastname: Flores Molina
authors.forename: Hermes
authors.initials: H
authors.lastname: Ilarraza Lomelí
authors.forename: Carlos
authors.initials: C
authors.lastname: Martínez Sánchez
authors.forename: Leonardo
authors.initials: L
authors.lastname: del Valle Mondragón
authors.forename: Fermín Alejandro
authors.initials: FA
authors.lastname: Tenorio López
authors.forename: Gustavo
authors.initials: G
authors.lastname: Pastelín Hernández
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy*; D000368:Aged; D004730:Endothelium, Vascular / Q000187:drug effects*; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood*; D018384:Oxidative Stress / Q000187:drug effects*; D011743:Pyrimidines / Q000627:therapeutic use*; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D009569:Nitric Oxide; D000068718:Rosuvastatin Calcium